reviewNature Reviews Drug DiscoveryDec 1, 2014Closed access

Targeting RAS–ERK signalling in cancer: promises and challenges

AAAhmed A. SamatarPIPoulikos I. Poulikakos

Mistras Group (United States) · Tisch Hospital · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,198
total citations
FWCI
36.28
Percentile
100%
References
139
Citations per year

Authors

2

Topics & keywords

Topics
Keywords
  • MAPK/ERK pathway
  • KRAS
  • Neuroblastoma RAS viral oncogene homolog
  • Cancer research
  • Drug development
  • Medicine
  • Trametinib
  • Effector
No related works found for this paper.